Transparency Market Research in its new report titled, “Radiation Proctitis Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the radiation proctitis treatment market. The TMR report anticipates that the rise in prevalence of prostate, rectal, and cervical cancers will drive the radiation proctitis treatment market during the forecast period i.e, 2018-2026. Moreover, increase in adoption of radiation therapy to treat cancer is projected to drive the radiation proctitis treatment market during the forecast period. However, adverse reactions of non-invasive drugs such as transient nausea and occasional vomiting are likely to hamper the radiation proctitis treatment market in the next few years, says the report.
The TMR report has split the global radiation proctitis treatment market on the basis of treatment type, distribution channel and geography. In terms of treatment type, the global radiation proctitis treatment market is segmented into non-invasive and invasive. The non-invasive segment can be classified into nonsterodial anti-inflammatory drugs, sucralfate, short chain fatty acids, hyperbaric oxygen, and antioxidants. The sucralfate drugs sub-segment is likely to expand at a rapid pace during the forecast period, as sucralfate agents such as pentosan polysulfate contain high sulfated polyanionic disaccharide compound that stimulates epithelial healing and forms a coating that helps to heal more quickly. On the basis of distribution channel, the global radiation proctitis treatment market is bifurcated into hospital pharmacies and medical stores. The hospital pharmacies segment is likely to expand at a significant pace during the forecast period, as radiation proctitis treatment is mostly performed in hospitals and patients feel convenient to purchase drugs through hospital pharmacies.
According to geographical perspective, the global radiation proctitis treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among these, North America dominates the global radiation proctitis treatment market. The region is projected to account for a significant share of the global market during the forecast period, due to rise in prevalence of rectal cancer in the region. According to the American Cancer Society in 2014, over 94,890 women will be diagnosed with gynecological cancer in the U.S. In Europe, incidence of prostate cancer is increasing among the geriatric population. This is projected to propel the radiation proctitis treatment market in the region during the forecast period. Increase in radiation exposure to treat various disease such as cancer is likely to propel the radiation proctitis treatment market in Asia Pacific during the forecast period. Prevalence of diseases that require frequent X-ray and radiation therapy is increasing in Central Africa. This is expected to augment the radiation proctitis treatment market in Middle East & Africa during the forecast period.
Key players operating in the global radiation proctitis treatment market are Chugai Pharmaceutical Co Ltd., GlaxoSmithKline plc, Nanjing Pharmaceutical Factory Co., Ltd., Allergan plc, Reckitt & Benckiser, Sun Pharmaceutical Industries Ltd., Northeast Pharmaceutical, Huanan Pharma, and Dr. Reddy Laboratories Ltd., among others.
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453